CA2444529C - Micellar drug delivery systems for hydrophobic drugs - Google Patents

Micellar drug delivery systems for hydrophobic drugs Download PDF

Info

Publication number
CA2444529C
CA2444529C CA2444529A CA2444529A CA2444529C CA 2444529 C CA2444529 C CA 2444529C CA 2444529 A CA2444529 A CA 2444529A CA 2444529 A CA2444529 A CA 2444529A CA 2444529 C CA2444529 C CA 2444529C
Authority
CA
Canada
Prior art keywords
composition
molecular weight
water soluble
hydrophobic
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2444529A
Other languages
English (en)
French (fr)
Other versions
CA2444529A1 (en
Inventor
Helen M. Burt
John K. Jackson
Jason Zastre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of CA2444529A1 publication Critical patent/CA2444529A1/en
Application granted granted Critical
Publication of CA2444529C publication Critical patent/CA2444529C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CA2444529A 2001-04-20 2002-04-22 Micellar drug delivery systems for hydrophobic drugs Expired - Fee Related CA2444529C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28488401P 2001-04-20 2001-04-20
US60/284,884 2001-04-20
PCT/CA2002/000542 WO2002085337A1 (en) 2001-04-20 2002-04-22 Micellar drug delivery systems for hydrophobic drugs

Publications (2)

Publication Number Publication Date
CA2444529A1 CA2444529A1 (en) 2002-10-31
CA2444529C true CA2444529C (en) 2010-11-23

Family

ID=23091881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2444529A Expired - Fee Related CA2444529C (en) 2001-04-20 2002-04-22 Micellar drug delivery systems for hydrophobic drugs

Country Status (11)

Country Link
US (3) US20040234472A1 (enExample)
EP (2) EP1392254B1 (enExample)
JP (1) JP2004532847A (enExample)
AT (1) ATE363898T1 (enExample)
CA (1) CA2444529C (enExample)
DE (1) DE60220519T2 (enExample)
DK (1) DK1392254T3 (enExample)
ES (1) ES2286244T3 (enExample)
NZ (1) NZ529647A (enExample)
PT (1) PT1392254E (enExample)
WO (1) WO2002085337A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085337A1 (en) * 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
DE20204258U1 (de) * 2002-03-16 2003-07-31 Rübben, Alexander, Dr.med., 52074 Aachen Stent mit Beschichtung (Vitastent 2)
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
CA2618404A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
ITMI20051826A1 (it) * 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
KR100678790B1 (ko) 2006-01-31 2007-02-02 (주)아모레퍼시픽 자외선 차단용 수중유형 유화 화장료 조성물
EP2370055A2 (en) * 2008-11-30 2011-10-05 University Of The Witwatersrand, Johannesburg Polymeric pharmaceutical dosage form in sustained release
WO2010127271A1 (en) 2009-04-30 2010-11-04 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
US8524784B2 (en) * 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
KR101721281B1 (ko) 2009-09-25 2017-04-10 위스콘신 얼럼나이 리서어치 화운데이션 치료제의 미셀 캡슐화
AU2011223448B8 (en) 2010-03-01 2015-10-15 Centre For Drug Research And Development Derivatized hyperbranched polyglycerols
KR101411349B1 (ko) * 2010-12-24 2014-06-25 주식회사 삼양바이오팜 생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
JP5651026B2 (ja) * 2011-01-21 2015-01-07 株式会社クレハ ポリグリコール酸組成物、ポリグリコール酸を含む樹脂成形品及び成形体、並びに、ポリグリコール酸の分解方法
US8834861B2 (en) 2011-03-10 2014-09-16 International Business Machines Corporation Polycarbonates for delivery of drugs and methods of preparation thereof
US20120283381A1 (en) * 2011-05-04 2012-11-08 Ryuta Tamiya Macroinitiator containing hydrophobic segment
ITRM20120169A1 (it) 2012-04-19 2013-10-20 Consiglio Nazionale Ricerche Dispositivo di rilascio di specie chimiche a controllo ottico
ES2938586T3 (es) 2012-06-27 2023-04-12 Medincell S A Liberación de fármacos biodegradables para composiciones hidrófobas
DK2879502T3 (en) 2012-07-30 2018-10-15 Matinas Biopharma Nanotechnologies Inc COCHLEATES PREPARED WITH SOYAPHOSPHATIDYLSERINE
US20150071860A1 (en) * 2013-09-09 2015-03-12 Coleen Pugh Cyclic peg coatings increase the blood circulation time of particles used in drug delivery applications
WO2018182509A1 (en) * 2017-03-28 2018-10-04 Agency For Science, Technology And Research Solvent-free method of encapsulating a hydrophobic active
EP3638311A4 (en) 2017-06-13 2020-12-16 The University of British Columbia COMPOSITIONS OF POLYMERIC PASTE FOR DRUG ADMINISTRATION
WO2020243523A1 (en) 2019-05-29 2020-12-03 Drexel University Microbubbles
US11826477B1 (en) * 2022-06-17 2023-11-28 Imam Abdulrahman Bin Faisal University Metal organic framework/porous silicate and/or aluminosilicate nanocarrier for blastocystosis treatment

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419340A (en) 1969-03-24 1983-12-06 University Of Delaware Controlled release of anticancer agents from biodegradable polymers
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4650913A (en) 1984-11-29 1987-03-17 E. I. Du Pont De Nemours And Company Sulfinate-initiated addition of perfluorinated iodides to olefins
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278949A (en) * 1991-03-12 1994-01-11 Hewlett-Packard Company Polygon renderer which determines the coordinates of polygon edges to sub-pixel resolution in the X,Y and Z coordinates directions
TW197439B (enExample) * 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
CA2071160A1 (en) * 1991-07-31 1993-02-01 Vittorio Farina Asymmetric synthesis of taxol side chain
US5283253A (en) * 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5350866A (en) * 1991-09-23 1994-09-27 Bristol-Myers Squibb Company 10-desacetoxytaxol derivatives
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) * 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5440056A (en) * 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5274137A (en) * 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5202448A (en) * 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
WO1994005282A1 (en) * 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696464B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5411984A (en) * 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU6361294A (en) 1993-03-09 1994-09-26 Enzon, Inc. Taxol-based compositions with enhanced bioactivity
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ATE154757T1 (de) 1993-07-19 1997-07-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5394637A (en) * 1993-09-10 1995-03-07 Hnizdor; Thomas A. Keeling bend fly hook
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5395850A (en) * 1994-03-10 1995-03-07 Bristol-Myers Squibb Company 6,7-epoxy paclitaxels
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
CH686865A5 (de) * 1994-06-15 1996-07-31 Gergely Gerhard Pharmazeutische Zubereitung mit einem hydrophoben Wirkstoff und einem Brausesystem, sowie Verfahren zur Herstellung der Zubereitung.
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5939454A (en) * 1995-08-17 1999-08-17 Basf Akdtiengesellschaft Fungicidal mixtures of an oxime ether carboxylic acit amide with a dithiocarbamate
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
WO1997027855A1 (en) 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6210717B1 (en) * 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
CA2316248A1 (en) 1997-12-23 1999-07-01 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
WO2002085337A1 (en) * 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6365173B1 (en) 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
KR20010010393A (ko) 1999-07-20 2001-02-05 김윤 소수성 고분자와 친수성 고분자의 생분해성 블록 공중합체 및이를 포함하는 약물 전달체 조성물
KR100360827B1 (ko) 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
US6369037B1 (en) 1999-10-19 2002-04-09 Cornell Research Foundation, Inc. Controlled release of doxorubicin
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
JP3523821B2 (ja) 2000-02-09 2004-04-26 ナノキャリア株式会社 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物
MXPA02010999A (es) * 2000-05-12 2003-03-10 Samyang Corp Metodo para la preparacion de micelas polimericas por medio de la separacion de fase de copolimero de bloque.
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2002240755B2 (en) 2001-03-13 2007-07-05 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
AU2002343681B2 (en) 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
BR0314767A (pt) 2002-06-11 2005-07-26 Ethypharm Sa Nanocápsulas lipidìcas furtivas, processos para a preparação das mesmas e uso das mesmas como um veìculo para princìpio(s) ativo(s)
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
FR2844477B1 (fr) 2002-09-18 2004-11-26 Nicolas Helou Dispositif integre dans une carte permettant d'obtenir par le souffle l'activation et/ou la desactivation d'un module lumineux ou sonore ou la combinaison des deux

Also Published As

Publication number Publication date
US20060189785A1 (en) 2006-08-24
PT1392254E (pt) 2007-06-29
EP1392254B1 (en) 2007-06-06
WO2002085337A1 (en) 2002-10-31
NZ529647A (en) 2007-05-31
US20090105351A1 (en) 2009-04-23
US20040234472A1 (en) 2004-11-25
WO2002085337B1 (en) 2003-02-06
US7875677B2 (en) 2011-01-25
ATE363898T1 (de) 2007-06-15
EP1800670A1 (en) 2007-06-27
EP1392254A1 (en) 2004-03-03
JP2004532847A (ja) 2004-10-28
CA2444529A1 (en) 2002-10-31
HK1063742A1 (en) 2005-01-14
DK1392254T3 (da) 2007-07-02
DE60220519T2 (de) 2007-09-27
ES2286244T3 (es) 2007-12-01
DE60220519D1 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
US7875677B2 (en) Micellar drug delivery systems for hydrophobic drugs
CA2430481C (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
CA2672551C (en) Biodegradable block copolymeric compositions for drug delivery
JP7210816B6 (ja) 医薬組成物
US20050042293A1 (en) Polymeric systems for drug delivery and uses thereof
AU2002222733A1 (en) Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof
CN103054794A (zh) 难溶性药物凝胶组合物及其制备方法
WO2022123480A1 (en) Material and method for treating cancer
US20110070320A1 (en) Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration
US20030228366A1 (en) Reconstitutable compositions of biodegradable block copolymers
HK1063742B (en) Micellar drug delivery systems for hydrophobic drugs
AU2002249045A1 (en) Micellar drug delivery systems for hydrophobic drugs
HK1132684A (en) Biodegradable block copolymeric compositions for drug delivery

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed